Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Fisetin to Reduce Systemic Senescence Indices
NCT07918261Phase 2Completed
- Sponsor
- Steadman Philippon Research Institute
- Start
- May 2023
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fisetin in cellular senescence (2 arms), sponsored by Steadman Philippon Research Institute. Primary endpoint: Change from baseline in levels of senescent PBMCs at 45 days. Started May 2023; status: completed.
02
Drugs
fisetin
03
Conditions
cellular senescence
Beyond the preview
Go deeper on NCT07918261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07918261.